Non-alcoholic fatty liver disease (NAFLD) includes a range of liver pathologies based on non-alcoholic fatty liver, defined by the presence of fat accumulation in more than 5% of hepatocytes by non-invasive imaging or histological assessment [1]. The global prevalence of NAFLD is approximately 25%, and NAFLD is the leading cause of cirrhosis and hepatocellular carcinoma [2]. NAFLD is considered the hepatic manifestation of the metabolic syndrome. However, the liver is not only a passive target but affects the pathogenesis of the metabolic syndrome and its complications [3]. Previous studies showed that there were mechanistic links between metabolic syndrome and atrial fibrillation (AF) susceptibility [4].
